Condition
Neuromuscular Blockade Reversal Agent
Total Trials
4
Recruiting
2
Active
3
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 4 (2)
Trial Status
Recruiting2
Active Not Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06962007Not ApplicableRecruitingPrimary
Sugammadex-Induced Clenching During Neuromuscular Blockade Reversal
NCT07666984Phase 4RecruitingPrimary
The Effect of Neostigmine and Sugammadex on the Optic Nerve Sheath Diameter
NCT06948409Active Not Recruiting
NMBA Reversal and Postoperative Urinary Retention
NCT04332627Phase 4CompletedPrimary
Comparison of QoR-15 in Laparoscopic Cholecystectomy: Sugammadex vs. Neostigmine
Showing all 4 trials